Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

enabeler 155 posts  |  Last Activity: Aug 2, 2015 6:44 PM Member since: Oct 23, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Probably a little crazy but i just have a feeling that when they fix the technical glitch, we could get a strong bounce as traders resume regular breathing.

    Sentiment: Buy

  • I feel much better now!

  • Reply to

    công ty dược phẩm Exelixis Message Board

    by neers87 Jul 8, 2015 11:58 AM
    enabeler enabeler Jul 8, 2015 12:28 PM Flag

    whoops, I meant BIS is up 4%, which indicates biotechs are being hit hard, and EXEL is not unusually lower than the rest.

  • Reply to

    công ty dược phẩm Exelixis Message Board

    by neers87 Jul 8, 2015 11:58 AM
    enabeler enabeler Jul 8, 2015 12:15 PM Flag

    I hope people don't start selling first and asking questions later.

    Lot of weird unknown issues affecting the digital and electronic nature of the financial system. So far, no panic , but the longer the NYSE is closed the more likelihood that panic might set in. I never made any trades today but I sure wish they would have let us know before the opening.

    BIS, the ultra short biotech ETF, is down over 4% so EXEL is not trading any worse than the group.

    Sentiment: Strong Buy

  • Round and round it goes, where it stops nobody knows.Talking heads, chart analysis, market blogs, yada, yada,yada.

    Bottom line...it is what it is, and as usual the retail investor gets trampled while the rich get richer.

    Sentiment: Strong Buy

  • Reply to

    EXEL SEC Filling 1934 Act

    by ninergizer Jul 7, 2015 1:18 PM
    enabeler enabeler Jul 7, 2015 1:29 PM Flag

    Why don't you call investor relations at EXEL (Susan Hubbard). She'll be glad to tell you what they're trying to hide.LOL

    Sentiment: Strong Buy

  • Once again, I'm just an amateur technician, but yesterday's low was lower than the day before and the high was higher than the day before. When this happens at a support level it is a fairly reliable indication of higher prices ahead.

    Sentiment: Strong Buy

  • enabeler enabeler Jul 6, 2015 8:56 AM Flag

    "I may jump in."

    Come on in, the water's is just fine, and with today's market over reaction to a Greek exit from the Euro, you should get a good entry point.

    Sentiment: Strong Buy

  • Reply to

    Exel management

    by holderstock Jul 4, 2015 2:24 PM
    enabeler enabeler Jul 5, 2015 7:02 PM Flag

    "thoughts?"

    Yeah, I got thoughts. Greece is .03% of the world's economy and I wish I had a lot more capital to take advantage of the free fall for the market tomorrow.

    Sentiment: Strong Buy

  • Reply to

    CTO

    by csanderson1805 Jul 2, 2015 3:39 PM
    enabeler enabeler Jul 3, 2015 3:04 PM Flag

    social, are you suggesting there were officers or directors of Exelixis that benefitted personally from this deal.
    "Exelixis and Boehringer Ingelheim Enter into Collaboration for Development of S1P1 Receptor Agonists in the Field of Autoimmune Diseases
    SOUTH SAN FRANCISCO, Calif. & INGELHEIM, Germany, May 07, 2009 (BUSINESS WIRE) -- Exelixis, Inc. (Nasdaq: EXEL) and Boehringer Ingelheim, a global pharmaceutical group of companies, headquartered in Germany, announced today that they have established an exclusive, worldwide collaboration with the aim to discover, develop and commercialize autoimmune disease therapies. The collaboration is focused on the discovery of sphingosine-1-phosphate type 1 receptor (S1P1) agonists. The S1P1 receptor is a central mediator of multiple pathways implicated in a variety of autoimmune diseases.
    Under the terms of the agreement, Exelixis will receive a $15 million upfront payment. In addition, Exelixis will potentially receive up to $339 million in milestone payments dependent on the successful achievement of development, regulatory and commercial program goals and royalties on sales of potential products commercialized under the collaboration.

    Exelixis and Boehringer Ingelheim will share responsibility for discovery activities and Boehringer Ingelheim will in addition have sole responsibility for all subsequent pre-clinical, clinical, regulatory, commercial and manufacturing activities.

    "This collaboration highlights Exelixis' ability to leverage our discovery capabilities and early-stage pipeline," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Our S1P1 agonist program has identified multiple analogs with potent in vivo activity. With this collaboration, we have the opportunity to transition the program to a partner with a track record of success in developing and commercializing autoimmune disease therapies while strengthening our financial position."

    "This agreement with Exelixis is a strategic fit to Boehringer Ingelheim's immunology research projects for the potential treatment of autoimmune diseases," said Prof. Andreas Barner, Chairman of the Board of Managing Directors and Head of Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim. "We will apply our expertise in immunology research and our global capabilities in drug development and commercialization to drive the joint project forward with the ultimate aim to help patients."

    Sentiment: Strong Buy

  • Reply to

    BRAF V600E

    by stimulustrader Jul 1, 2015 11:33 AM
    enabeler enabeler Jul 2, 2015 10:03 PM Flag

    Great stuff joe, this should be disseminated to all the serious members of this message board.

    Sentiment: Strong Buy

  • Reply to

    CTO

    by csanderson1805 Jul 2, 2015 3:39 PM
    enabeler enabeler Jul 2, 2015 9:58 PM Flag

    The PDUFA delay from Aug to Nov is also a little fishy as well, considering how strong the trial results were in coBrim.

    Sentiment: Strong Buy

  • Reply to

    any chartist here

    by mj525252 Jul 2, 2015 1:28 PM
    enabeler enabeler Jul 2, 2015 2:46 PM Flag

    Just an amateur chartist; but if you want me to comment on market I will, but please don't judge it and try to argue with my view because charts, much like women and men, are in the eye of the beholder.

    The DJII is currently trading at or very near the 200 DMA where it has bounced off of for the last 3 years. Only in October of last year did the DJII fall below the 200 DMA and created a tremendous buying opportunity. Stochastics are in a buy zone, RSI might go a little lower but it is approaching the buy zone, and MACD is more neutral and could go either way. If you are long I would advise you to stay long ( Talk about going out on the limb), if you are looking to start a position I think this is very near the right moment. If you're bearish I think you missed the sell opportunity, for now.

  • Reply to

    Convertible debt

    by alexp1112 Jun 30, 2015 4:32 PM
    enabeler enabeler Jun 30, 2015 8:07 PM Flag

    " PPS of 7.5"

    I'll take 7.5 PPS, but PFS better be a lot higher.

    Sentiment: Strong Buy

  • Reply to

    Convertible debt

    by alexp1112 Jun 30, 2015 4:32 PM
    enabeler enabeler Jun 30, 2015 6:51 PM Flag

    Of course, you're both assuming METEOR will be successful, which i do too. However, should METEOR fail or not be much better than expected there is a good chance that they will not be able to sell the ex-US rights and then we have to deal with the hedge fund shorties continuing to manipulate the heck out of it until they get their pound of flesh.

    The action in the stock lately (despite the 10-15% correction), points to a success, but with EXEL and MMM you can just never be sure until it's sure.

    Sentiment: Strong Buy

  • Reply to

    SHORTS DIE AGAIN..hahaha. ..go to hell

    by bugbgon Jun 30, 2015 3:01 PM
    enabeler enabeler Jun 30, 2015 3:28 PM Flag

    Do you know something we don't?

    Sentiment: Strong Buy

  • Reply to

    PCF's List of Provocative Questions

    by wilderguide Jun 30, 2015 12:51 PM
    enabeler enabeler Jun 30, 2015 2:21 PM Flag

    Pretty interesting stuff (data) and I was surprised that we heard no mention of METEOR or cabo; but maybe they were sticking to only drugs currently approved for mRCC.

    Sentiment: Strong Buy

  • Another positive blog/article in Motley Fool today. He has stuck by EXEL through thick and thin.

    Sentiment: Strong Buy

  • Reply to

    Huge upside volume at close on a Friday!

    by enabeler Jun 29, 2015 9:31 AM
    enabeler enabeler Jun 29, 2015 5:36 PM Flag

    H'mm, that worked well. LOL

    Market dynamics (worst day in 3 years didn't help) were mostly responsible for the quick 10% pullback from the 4.18 high last week. The upside catalysts are still out there (METEOR, Euro approval for cobi/vemu combo, FDA approval of the same), so hang on, this is not unusual for a biotech that just went up 230% since Xmas, and the best is yet to come.

    Sentiment: Strong Buy

  • Reply to

    What's wrong with this picture?

    by enabeler Jun 24, 2015 12:22 PM
    enabeler enabeler Jun 29, 2015 5:17 PM Flag

    Well, it looks like the one with $0 revenues wins, of course, the market wouldn't have it any other way. If you own JUNO congratulations.

    Sentiment: Strong Buy

EXEL
6.12+0.27(+4.41%)Aug 3 4:00 PMEDT